Get the Stockscreener App
9.67
8.65%
0.77
After Hours:
9.79
0.12
+1.24%
4 D Molecular Therapeutics Inc stock is traded at $9.67, with a volume of 1.89M.
It is up +8.65% in the last 24 hours and up +42.00% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$8.90
Open:
$8.9
24h Volume:
1.89M
Relative Volume:
1.62
Market Cap:
$451.61M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-3.6353
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
+15.12%
1M Performance:
+42.00%
6M Performance:
+267.68%
1Y Performance:
+5.45%
1-Day Range:
$8.50
$9.70
1-Week Range:
$8.1101
$10.03
52-Week Range:
$2.235
$10.03
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
9.67 | 415.65M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
4D Molecular Therapeutics, Inc. announced that it expects to receive $11 million in funding from Cystic Fibrosis Foundation - MarketScreener
Will 4D Molecular Therapeutics Inc. outperform the marketJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
4D Molecular Therapeutics Receiving $11 Million in Funding for Cystic Fibrosis Study - MarketScreener
Published on: 2025-10-13 08:38:02 - newser.com
How institutional ownership impacts 4D Molecular Therapeutics Inc. stockTrade Ideas & Precise Buy Zone Tips - newser.com
Is it too late to sell 4D Molecular Therapeutics Inc.Market Rally & Weekly Breakout Opportunity Watchlist - newser.com
4D Molecular (FDMT) Gains $11M Support for Cystic Fibrosis Treat - GuruFocus
Is it time to cut losses on 4D Molecular Therapeutics Inc.Trade Signal Summary & Risk Managed Investment Strategies - newser.com
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation - Stock Titan
When is the best time to exit 4D Molecular Therapeutics Inc.Rate Hike & Risk Managed Investment Entry Signals - newser.com
Momentum divergence signals in 4D Molecular Therapeutics Inc. chart2025 Top Decliners & Short-Term Swing Trade Alerts - newser.com
Will 4D Molecular Therapeutics Inc. see short term momentumJuly 2025 Trade Ideas & Long-Term Growth Portfolio Plans - newser.com
4D Molecular Therapeutics Inc Stock Analysis and ForecastGlobal Market Influence & Access Powerful Market Insights - earlytimes.in
Real time alert setup for 4D Molecular Therapeutics Inc. performancePortfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com
What drives 4D Molecular Therapeutics Inc stock priceTrade Execution Strategies & Free Stock Chart Pattern Guides - earlytimes.in
Statistical indicators supporting 4D Molecular Therapeutics Inc.’s strength2025 Valuation Update & Weekly High Return Opportunities - newser.com
4D Molecular Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:FDMT - Benzinga
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Is 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth? - Yahoo Finance
How 4D Molecular Therapeutics Inc. stock responds to policy changesJuly 2025 Outlook & Technical Pattern Based Buy Signals - newser.com
What MACD signals say about 4D Molecular Therapeutics Inc.2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
What the charts say about 4D Molecular Therapeutics Inc. todayProduct Launch & Accurate Buy Signal Alerts - newser.com
4D Molecular Therapeutics says on Sept 30, appointed Ashoo Gupta as principal financial officerSEC filing - MarketScreener
4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors (NASDAQ:FDMT) - Seeking Alpha
Can momentum traders help lift 4D Molecular Therapeutics Inc.Stock Surge & Real-Time Market Sentiment Alerts - newser.com
What analysts say about 4D Molecular Therapeutics Inc stockMarket Insider Reports & Free Explosive Wealth Accumulation - earlytimes.in
Is 4D Molecular Therapeutics Inc. stock reversal real or fakeWeekly Stock Summary & Consistent Growth Equity Picks - newser.com
News impact scoring models applied to 4D Molecular Therapeutics Inc.July 2025 Summary & Expert Approved Momentum Trade Ideas - newser.com
Bizily Scott sells 4D Molecular Therapeutics (FDMT) stock worth $19,256 By Investing.com - Investing.com Canada
Bizily Scott sells 4D Molecular Therapeutics (FDMT) stock worth $19,256 - Investing.com India
4D Molecular Therapeutics Inc. stock daily chart insightsWeekly Trend Report & Verified Technical Trade Signals - newser.com
Is 4D Molecular Therapeutics Inc. stock bottoming outStop Loss & Accurate Entry/Exit Alerts - newser.com
Custom strategy builders for tracking 4D Molecular Therapeutics Inc.2025 Price Momentum & AI Forecasted Entry and Exit Points - newser.com
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):